Johnson Investment Counsel’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Johnson Investment Counsel’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,469	Closed	-$354K	–	717
2023 Q2	$354K	Hold	3,469	–	–	﹤0.01%	538
2023 Q1	$315K	Buy	+3,469	New	+$204K	﹤0.01%	540
2021 Q4	–	Sell	-3,469	Closed	-$349K	–	687
2021 Q3	$349K	Hold	3,469	–	–	﹤0.01%	515
2021 Q2	$491K	Sell	3,469 -400	-10%	-$45.2K	0.01%	443
2021 Q1	$386K	Hold	3,869	–	–	0.01%	468
2020 Q4	$478K	Hold	3,869	–	–	0.01%	407
2020 Q3	$377K	Hold	3,869	–	–	0.01%	426
2020 Q2	$604K	Hold	3,869	–	–	0.01%	362
2020 Q1	$558K	Hold	3,869	–	–	0.01%	344
2019 Q4	$791K	Hold	3,869	–	–	0.01%	354
2019 Q3	$311K	Buy	3,869 +400	+12%	+$33.9K	0.01%	493
2019 Q2	$327K	Hold	3,469	–	–	0.01%	491
2019 Q1	$296K	Buy	+3,469	New	+$288K	0.01%	504
2018 Q4	–	Sell	-3,469	Closed	-$283K	–	658
2018 Q3	$283K	Buy	+3,469	New	+$244K	0.01%	533

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Johnson Investment Counsel's RETA Position: Q3 2023 in Review

Johnson Investment Counsel sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 3,469 shares — an estimated $354K sold.

Johnson Investment Counsel first reported a position in RETA in Q3 2018 and held it in 14 quarters. The position peaked at $791K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Johnson Investment Counsel reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Johnson Investment Counsel sold 3,469 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $354K.
Johnson Investment Counsel first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 14 quarters.
Johnson Investment Counsel's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $791K in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Johnson Investment Counsel's 13F filing for Q3 2023, filed 13 Nov 2023.